Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Comprehensive Single-Cell Transcriptional Analysis of Aromatase Inhibitor-Resistant Breast Cancer

NCT05447910 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT05447910
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05447910 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Comprehensive Single-Cell Transcriptional Analysis of Aromatase Inhibitor-Resistant Breast Cancer
Lead sponsor
Mayo Clinic
Phase
Observational
Overall status
Terminated
Start date
July 21, 2022
Completion date
September 27, 2023
Enrollment
21 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast adenocarcinoma, invasive breast carcinoma, resectable breast carcinoma